ATE401349T1 - Monoklonale antikörper gegen das map-protein und verfahren zu dessen anwendung bei der behandlung bzw. prävention von infektionen - Google Patents

Monoklonale antikörper gegen das map-protein und verfahren zu dessen anwendung bei der behandlung bzw. prävention von infektionen

Info

Publication number
ATE401349T1
ATE401349T1 AT01988737T AT01988737T ATE401349T1 AT E401349 T1 ATE401349 T1 AT E401349T1 AT 01988737 T AT01988737 T AT 01988737T AT 01988737 T AT01988737 T AT 01988737T AT E401349 T1 ATE401349 T1 AT E401349T1
Authority
AT
Austria
Prior art keywords
treatment
map protein
bacteria
infections
prevention
Prior art date
Application number
AT01988737T
Other languages
English (en)
Inventor
Joseph Patti
Paul Domanski
Pratisksha Patel
Original Assignee
Inhibitex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibitex Inc filed Critical Inhibitex Inc
Application granted granted Critical
Publication of ATE401349T1 publication Critical patent/ATE401349T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT01988737T 2000-10-20 2001-10-22 Monoklonale antikörper gegen das map-protein und verfahren zu dessen anwendung bei der behandlung bzw. prävention von infektionen ATE401349T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24183200P 2000-10-20 2000-10-20
US27728701P 2001-03-21 2001-03-21

Publications (1)

Publication Number Publication Date
ATE401349T1 true ATE401349T1 (de) 2008-08-15

Family

ID=26934627

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01988737T ATE401349T1 (de) 2000-10-20 2001-10-22 Monoklonale antikörper gegen das map-protein und verfahren zu dessen anwendung bei der behandlung bzw. prävention von infektionen

Country Status (8)

Country Link
US (1) US20020164337A1 (de)
EP (1) EP1334131B1 (de)
JP (1) JP2004512040A (de)
AT (1) ATE401349T1 (de)
AU (1) AU2002224437A1 (de)
CA (1) CA2425000A1 (de)
DE (1) DE60134881D1 (de)
WO (1) WO2002034788A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434119A1 (en) 2001-01-10 2002-10-03 The Texas A & M University System Method of preventing t cell-mediated responses by the use of the major histocompatibility complex class ii analog protein (map protein) from staphylococcus aureus
US7463573B2 (en) 2005-06-24 2008-12-09 Nanochip, Inc. Patterned media for a high density data storage device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648240A (en) * 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
WO1996039518A1 (en) * 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
US6118044A (en) * 1997-11-14 2000-09-12 Sankyo Company, Limited Transgenic animal allergy models and methods for their use
IL141639A (en) * 1998-08-31 2005-12-18 Inhibitex Inc Multicomponent vaccines
CA2434119A1 (en) * 2001-01-10 2002-10-03 The Texas A & M University System Method of preventing t cell-mediated responses by the use of the major histocompatibility complex class ii analog protein (map protein) from staphylococcus aureus

Also Published As

Publication number Publication date
EP1334131B1 (de) 2008-07-16
CA2425000A1 (en) 2002-05-02
DE60134881D1 (de) 2008-08-28
JP2004512040A (ja) 2004-04-22
EP1334131A1 (de) 2003-08-13
EP1334131A4 (de) 2005-07-20
AU2002224437A1 (en) 2002-05-06
US20020164337A1 (en) 2002-11-07
WO2002034788A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
ATE524195T1 (de) Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
DE60101265D1 (de) Behandlung von augenschmerzen
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
ATE309271T1 (de) Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen
ATE109624T1 (de) Bakteriocine enthaltende zusammensetzungen zur verwendung als verbesserte breitspektrum- bakterizide und verfahren zur verhütung und behandlung von mikrobiellen infektionen.
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
NO20055722D0 (no) Antiseptiske preparater, fremgangsmater og systemer
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
ATE313328T1 (de) Verfahren zur behandlung von mittelohrinfektionen
DE69940404D1 (de) Multikomponenten Impfstoffe gegen Staphylococcus aureus
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
ATE531419T1 (de) Vorrichtung zur verabreichung von therapeutischen mitteln
ATE290548T1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE69631381T2 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
WO2007053176A3 (en) Method of protecting against staphylococcal infection
DE60032915D1 (de) Gallium komplexe von 3-hydroxy-4-pyronen zur behandlung von durch intrazelluläre prokaryoten, dns- und retro-viren verursachten infektionen
DE60134881D1 (de) Monoklonale antikörper gegen das map-protein und verfahren zu dessen anwendung bei der behandlung bzw. prävention von infektionen
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE303816T1 (de) Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
WO2000063386A3 (en) Prevention, diagnosis and treatment of lyme disease
DE69615685D1 (de) Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen
WO2005010167A3 (en) Antibodies to the fbsa protein of streptococcus agalactiae and their use in treating or preventing infections
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties